Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Multiple Sclerosis: Update Bulletin #2 [May 2018]

Product Code:
596200976
Publication Date:
May 2018
Format:
PDF
Price:
£910

This edition presents key opinion leader (KOL) views on recent developments in the multiple sclerosis (MS) market. Topics covered include: Celgene’s announcement that it has received a refusal-to-file letter from the FDA concerning ozanimod for the treatment of patients with relapsing forms of MS; Novartis announcing that it plans to seek FDA approval of siponimod as a therapy for secondary progressive multiple sclerosis (SPMS); as well as GeNeuro and Servier announcing positive results at 12 months from the Phase IIb CHANGE-MS study of GNbAC1.

Business Questions:

  • What are KOLs’ reactions to the FDA’s refusal-to-file letter for ozanimod?
  • According to KOLs, what challenges await ozanimod in the future?
  • How do KOLs view siponimod’s Phase III EXPAND data and what role will this drug have as a therapy for SPMS?
  • If approved, how will siponimod be prescribed?
  • According to experts, how clinically attractive is GnAC1 as a therapy for MS?






customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved